Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series

Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S and Del Mastro L: CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 8(608)2018.PubMed/NCBI View Article : Google Scholar

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11(R77)2009.PubMed/NCBI View Article : Google Scholar

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16:25–35. 2015.PubMed/NCBI View Article : Google Scholar

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925–1936. 2016.PubMed/NCBI View Article : Google Scholar

Cristofanilli M, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17:425–439. 2016.PubMed/NCBI View Article : Google Scholar

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, et al: Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 29:1748–1754. 2018.PubMed/NCBI View Article : Google Scholar

Breast Cancer NCCN guidelines, vers. 3.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, et al: 4th ESO-esmo international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 29:1634–1657. 2018.PubMed/NCBI View Article : Google Scholar

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Europ J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar

Brookmeyer R and Crowley JA: A confidence interval for the median survival time. Biometrics. 38:29–41. 1982.

R Core Team R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2017 https://www.R-project.org/.